Navtemadlin-Based Therapy Could Drive Change in the Myelofibrosis Treatment Paradigm
John Mascarenhas, MD, discusses navtemadlin’s mechanism of action and its potential to shift the myelofibrosis treatment landscape
Related Articles
China’s NMPA Approves Taletrectinib in Previously Treated ROS1+ Advanced NSCLC
China’s NMPA has approved taletrectinib for locally advanced or metastatic ROS1-positive non–small cell lung cancer after a previous ROS1 TKI.
Amyloidosis Sessions: Highlights from ASH 2024 | VJHemOnc
Welcome to The Amyloidosis Sessions brought to you by the Video Journal of Hematology and Hematological Oncology (VJHemOnc). This exclusive session features experts Vaishali Sanchorawala…
Ongoing replication stress tolerance and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancer
Nature Cancer – Sears and colleagues found that ongoing replication stress pathways and T cell clonal responses differentiate liver and lung recurrence and are associated…
Annals of Surgical Oncology – Society of Surgical Oncology
With over 25 years of publication excellence, the Annals of Surgical Oncology is the leading resource for cancer surgeons around the globe.
A Look at Poor Outcomes in Triple-Class Exposed Multiple… : Oncology Times
An abstract is unavailable.
Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma
Nature Cancer – Swanton and colleagues present a clonal expression signature, ORACLE, which, in combination with clinicopathological and molecular risk factors, can predict survival of…
BTK Degraders Look to Fill Unmet Need for Patients With Pretreated B-Cell Malignancies
Michael T. Tees, MD, MPH, describes how BTK degraders represent a promising class of agents, highlighting the agent AC676 that is currently under evaluation.
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
Zongertinib demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non–small cell lung cancer.
The role of molecular tumor boards in breast cancer care
Jenna Canzoniero, MD, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, explores the critical role of molecular tumor boards (MTB) in guiding oncologists through complex…
Crunching the numbers for next-gen COVID-19 vaccines
BARDA tapped a team of Fred Hutch Cancer Center biostatisticians to determine the biomarkers that will serve as predictors of protective responses in next-generation COVID-19…
